This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Alopecia
and you are
between 18 and 49
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).

Provided treatments

  • Drug: setipiprant
  • Drug: placebo
Tris trial is registered with FDA with number: NCT02781311. The sponsor of the trial is Allergan and it is looking for 169 volunteers for the current phase.
Official trial title:
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males